Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]
Ann Rheum Dis. 2015 Sep 15. doi:10.1136/ annrheumdis-2015-207760
Arthritis Rheumatol. 2015;67(1):117–127
Arthritis Res Ther. 2014;16(4):R158
Arthritis Rheumatol. 2014 Jun 18. [Epub ahead of print]
Rheumatology doi:10.1093/rheumatology/ket414
J Pharmacol Exp Ther. 2013. DOI:10.1124/jpet.113.209304
Basic Clin Pharmacol Toxicol. 2013 Oct 24. doi: 10.1111/bcpt.12164
Pharmacological Research 2013; 76:1–8
Journal of Hematology & Oncology 2013;6:59